Remimazolam vs Desflurane for General Anesthesia for Ablation of Arrhythmia

Seoul National University

Status and phase: Completed; Phase 4

Conditions: Remimazolam; Arrhythmia; General Anesthesia; Desflurane; Cryoablation

Treatments: Drug: Remimazolam besylate

Study type: Interventional

Funder types: Other

Identifiers

NCT05486377

B-2205-757-001

Details and patient eligibility

About

In anesthesia for ablation for cardiac arrhythmias, abrupt hemodynamic changes or fatal arrhythmias can be seen frequently. Remimazolam is a novel ultra-short acting benzodiazepine that provides good hemodynamic stability compared to conventional anesthetic agents. This study aims to investigate whether remimazolam reduces vasoactive agent use during cryo/radiofrequancy ablation under general anesthesia, compared to desflurane(RCT).

Enrollment: 96 patients

Sex: All

Ages: 20 to 105 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• =or > 20 years
• Admission for General anesthesia for RFCA or cryoablation procedure

Exclusion criteria

• No severe adverse effect history or hypersensitivity of benzodiazepines or its additives
• Acute alcoholic intoxication state
• Coma or shock state due to other condition than heart problem.
• Acute narrow-angle glaucoma

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

96 participants in 2 patient groups

Remimazolam

Experimental group

Description:

General anesthesia with remimazolam-remifentanil TIVA.

Treatment:

Drug: Remimazolam besylate

Desflurane

No Intervention group

Description:

General anesthesia with maintaining with desflurane (induction:PPF, remifentanil CIV)